Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 233

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy

Open access
Koikawa, Kazuhiro, Kibe, Shin, Suizu, Futoshi, Sekino, Nobufumi, Kim, Nami, Manz, Theresa D., Pinch, Benika J., Akshinthala, Dipikaa, Verma, Ana, Gaglia, Giorgio, Nezu, Yutaka, Ke, Shizhong, Qiu, Chenxi, Ohuchida, Kenoki, Oda, Yoshinao, Lee, Tae Ho, Wegiel, Babara, Clohessy, John G., London, Nir, Santagata, Sandro, Wulf, Gerburg M., Hidalgo, Manuel, Muthuswamy, Senthil K., Nakamura, Masafumi, Gray, Nathanael S., Zhou, Xiao Zhen, Lu, Kun Ping · 2021 · Cell

Abstract

SUMMARY Pancreatic ductal adenocarcinoma (PDAC) is characterized by notorious resistance to current therapies attributed to inherent tumor heterogeneity and highly desmoplastic and immunosuppressive tumor microenvironment (TME). Unique proline isomerase Pin1 regulates multiple cancer pathways, but its role in the TME and cancer immunotherapy is unknown. Here we find that Pin1 is overexpressed both in cancer cells and cancer-associated fibroblasts (CAFs), and correlates with poor survival in PDAC patients. Targeting Pin1 using clinically available drugs induces complete elimination or sustained remissions of aggressive PDAC by synergizing with anti-PD-1 and gemcitabine in diverse model systems. Mechanistically, Pin1 drives the desmoplastic and immunosuppressive TME by acting on CAFs, and induces lysosomal degradation of the PD-1 ligand PD-L1 and the gemcitabine transporter ENT1 in cancer cells, besides activating multiple cancer pathways. Thus, Pin1 inhibition simultaneously blocks multiple cancer pathways, disrupts the desmoplastic and immunosuppressive TME, and upregulates PD-L1 and ENT1, rendering PDAC eradicable by immunochemotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cell.2021.07.020

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 29 references

Cited by

See all 233

Metadata

Authors
Koikawa, K., Kibe, S., Suizu, F., Sekino, N., Kim, N., Manz, T. D., Pinch, B. J., Akshinthala, D., Verma, A., Gaglia, G., Nezu, Y., Ke, S., Qiu, C., Ohuchida, K., Oda, Y., Lee, T. H., Wegiel, B., Clohessy, J. G., London, N., Santagata, S., Wulf, G. M., Hidalgo, M., Muthuswamy, S. K., Nakamura, M., Gray, N. S., Zhou, X. Z., & Lu, K. P.
Venue
Cell
Publisher
Elsevier BV
Published
2021-09
Volume
184
Issue
18
Pages
4753-4771.e27
ISSN
0092-8674 (ISSN-L)
OpenAlex
W3192369129
Cited by
233
References
29
FWCI
11.07
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy. https://app.cochat.ai/papers/10.1016/j.cell.2021.07.020
The paper
Koikawa, K., Kibe, S., Suizu, F., Sekino, N., Kim, N., Manz, T. D., Pinch, B. J., Akshinthala, D., Verma, A., Gaglia, G., Nezu, Y., Ke, S., Qiu, C., Ohuchida, K., Oda, Y., Lee, T. H., Wegiel, B., Clohessy, J. G., London, N., . . . Lu, K. P. (2021). Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy. Cell. https://doi.org/10.1016/j.cell.2021.07.020

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.